Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system.

Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes. Its ...

The pace of Insulet's innovation has quickened and has allowed the firm to come on strong. We think Insulet benefited from Johnson & Johnson's exit from the pump market, especially for the pediatric ...

The Centers for Disease Control and Prevention (CDC) state that in the last 20 years, the number of adults diagnosed with diabetes has more than doubled. The primary treatment for type 1 diabetes is ...

With little direct competition in patch pumps, Insulet PODD has been able to convert more users to its innovative, tubeless insulin pump. We expect meaningful profitability gains over the next five ...

Using an insulin pump is an act of profound trust. Diabetic patients wear their insulin pumps at virtually all hours, relying on the medical machinery to administer doses of a potentially lethal ...

Ahead of a planned acquisition by Medtronic, it’s not all smooth sailing for EOFlow. The South Korean company makes a waterproof, disposable insulin patch pump that can hold up to 3.5 days’ worth of ...

MADRID — Airplane travel consistently causes insulin pumps to over-deliver a little over half a unit on takeoff and under-deliver a bit less on landing, new research found. This phenomenon is due to ...